

Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes

Charlotte B. Wagner,¹ Ken Boucher,¹ Adrienne Nedved,² Ivana N. Micallef,² Sanjal Desai,³ Haris Hatic,⁴ Gaurav Goyal,⁴ Erin Zacholski,⁵ Amanda Fegley,⁵ Audrey M. Sigmund,⁶ David A. Bond,⁶ Courtney Samuels,⁷ Manali K. Kamdar,⁷ Sheeba Ba Aqeel,⁸ Pallawi Torke,⁸ Kira MacDougall,⁹ Azra Borogovac,⁹ Sridevi Rajeeve,¹⁰ Suchitra Sundaram,¹⁰ Kalub Fedak,¹¹ Dipenkumar Modi,¹¹ Elizabeth Travers,¹² Sabarish Ayyappan,¹³ Nitin Chilakamarri,¹⁴ Elizabeth A. Brem,¹⁴ Daniel A. Ermann,¹ Lindsey A. Fitzgerald,¹ Boyu Hu,¹ Deborah M. Stephens¹ and Harsh Shah¹

¹University of Utah Huntsman Cancer Institute, Salt Lake City, UT; ²Mayo Clinic, Rochester, MS; ³University of Minnesota, Twin Cities of Minneapolis and Saint Paul, MN; ⁴University of Alabama Medicine, Birmingham, AL; ⁵Virginia Commonwealth University Health, Richmond, VA; ⁶The Ohio State University, Columbus, OH; ⁷University of Colorado Cancer Center, Aurora, CO; ⁸Roswell Park Comprehensive Cancer Center, Buffalo, NY; ⁹University of Oklahoma Health Sciences Center, Oklahoma, OK; ¹⁰Tisch Cancer Institute at Mount Sinai, New York, NY; ¹¹Karmanos Cancer Institute, Detroit, MI; ¹²University of Kentucky HealthCare, Lexington, KY; ¹³University of Iowa Hospitals and Clinics, Iowa City, IA and ¹⁴University of California, Irvine, CA, USA

[°]Current address: City of Hope Medical Center, Duarte, CA, USA

Correspondence: H. Shah
harsh.shah@hci.utah.edu


Received: January 19, 2023.
Accepted: April 19, 2023.
Early view: April 27, 2023.

<https://doi.org/10.3324/haematol.2023.282780>

©2023 Ferrata Storti Foundation
Published under a CC-BY license

Supplemental Figure 1: Time Independent Analysis for Progression Free Survival based on total cumulative dose

Fraction of Total Dose 76-100% 51-75% 1-50%



Number at risk

76-100%	39	32	17	1
51-75%	33	25	11	1
1-50%	46	26	7	0